PDL BioPharma, Inc. (NASDAQ:PDLI) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 1st. Analysts expect PDL BioPharma to post earnings of $0.13 per share for the quarter.

PDL BioPharma (NASDAQ:PDLI) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.17. PDL BioPharma had a return on equity of 9.07% and a net margin of 23.03%. The company had revenue of $143.80 million for the quarter, compared to the consensus estimate of $56.30 million. During the same quarter last year, the business posted $0.09 EPS. PDL BioPharma’s quarterly revenue was up 584.8% compared to the same quarter last year. On average, analysts expect PDL BioPharma to post $0.69 EPS for the current fiscal year and $0.63 EPS for the next fiscal year.

PDL BioPharma, Inc. (NASDAQ:PDLI) opened at 3.30 on Wednesday. PDL BioPharma, Inc. has a 12-month low of $1.93 and a 12-month high of $3.77. The company has a market cap of $508.46 million, a P/E ratio of 7.59 and a beta of 0.49. The firm’s 50-day moving average price is $3.34 and its 200-day moving average price is $2.67.

PDL BioPharma declared that its Board of Directors has initiated a stock repurchase plan on Monday, September 25th that permits the company to buyback $25.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Several equities analysts recently issued reports on the company. BidaskClub lowered PDL BioPharma from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Piper Jaffray Companies restated a “buy” rating and set a $4.00 price target on shares of PDL BioPharma in a research note on Thursday, August 10th. Finally, Zacks Investment Research upgraded PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, August 16th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. PDL BioPharma presently has an average rating of “Buy” and an average target price of $3.50.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/25/pdl-biopharma-inc-pdli-set-to-announce-earnings-on-wednesday.html.

PDL BioPharma Company Profile

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Earnings History for PDL BioPharma (NASDAQ:PDLI)

Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.